Mycobacteria Registry Study: Prospective Observational Study in Austria
Launched by LUDWIG BOLTZMANN INSTITUTE FOR LUNG HEALTH · Jul 22, 2024
Trial Information
Current as of August 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, known as the Mycobacteria Registry Study, is focused on understanding the risk factors that can lead to serious health issues or death from infections caused by Mycobacterium tuberculosis (the bacteria that causes tuberculosis) and non-tuberculous mycobacteria (other related bacteria). The goal of the study is to gather information about patients' experiences and treatment outcomes as they receive their usual medical care. By collecting this data, researchers hope to learn more about how effective current treatments are and what factors might put patients at greater risk.
To participate in this study, individuals must be at least 18 years old and diagnosed with either tuberculosis or a non-tuberculous mycobacterial infection. Importantly, participants will not receive any additional treatments from the study; instead, the focus is on observing their ongoing care. If you're eligible and choose to take part, you'll be helping to provide valuable insights that can improve understanding and treatment for these infections in Austria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with Mycobacterium tuberculosis or non-tuberculous mycobacteria infection
- • individuals aged 18 years or older
- • written informed consent
- Exclusion Criteria:
- • to not comprehend and rightfully judge participation
About Ludwig Boltzmann Institute For Lung Health
The Ludwig Boltzmann Institute for Lung Health is a leading research institution dedicated to advancing the understanding and treatment of respiratory diseases. With a strong focus on translational research, the Institute integrates clinical and laboratory studies to develop innovative therapies and improve patient outcomes. Collaborating with a network of academic, clinical, and industry partners, the Institute aims to bridge the gap between scientific discovery and clinical application, fostering a multidisciplinary approach to lung health research. Through its commitment to excellence and innovation, the Ludwig Boltzmann Institute is at the forefront of addressing complex challenges in respiratory medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Vienna, , Austria
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported